PEMF for
Avascular Necrosis.

July 2026 · 10 min read · Bone Health Protocol

What Is Avascular Necrosis?

Avascular necrosis (AVN), also called osteonecrosis, is the death of bone tissue due to interrupted blood supply. Without adequate circulation, the bone's cellular matrix collapses — leading to progressive structural failure, joint surface collapse, and ultimately severe osteoarthritis requiring joint replacement. The femoral head (hip) is the most commonly affected site, accounting for approximately 10% of all total hip replacements in high-income settings. The medial femoral condyle (knee), humeral head (shoulder), talus, and scaphoid are also affected.

AVN is classified into non-traumatic and traumatic subtypes. The leading causes of non-traumatic AVN are corticosteroid use (30–40% of cases), excessive alcohol consumption (20–30%), and idiopathic origin. Post-COVID AVN — driven by high-dose dexamethasone and methylprednisolone protocols used in 2020–2022 — has generated a significant new patient cohort that Philippine orthopedic clinics are now seeing in volume.

The Ficat & Arlet Staging System

Stage at presentation determines treatment eligibility and expected PEMF benefit. The most widely used classification is the Ficat & Arlet system (1980), later refined by the Association Research Circulation Osseous (ARCO):

The critical clinical window is Stage I–II, where the joint surface remains intact and viable. Patients who progress to Stage III without intervention have significantly worse outcomes from any non-surgical modality.

How PEMF Targets the Necrotic Zone

Four parallel mechanisms explain PEMF's activity in avascular bone:

1. Osteoblast differentiation via BMP-2/BMP-7 upregulation. Pulsed electromagnetic fields stimulate the production of bone morphogenetic proteins, promoting differentiation of mesenchymal stem cells into osteoblasts within the necrotic zone. This is the same mechanism underlying PEMF's FDA 510(k)-cleared indication for bone growth stimulation (1979) and non-union healing.
2. Angiogenesis via VEGF upregulation. PMC4959873 demonstrated PEMF-induced VEGF and angiogenic factor expression in musculoskeletal tissue. In AVN, where the bone's blood supply is already compromised, this angiogenic stimulus is the primary rationale for PEMF's potential to restore viable vascularity within the necrotic zone.
3. Suppression of osteoclast-dominant remodeling. AVN creates an environment where osteoclasts (bone-resorbing cells) outpace osteoblasts. PEMF shifts the OPG/RANKL ratio (per PMID 35864717 meta-analysis: PEMF significantly increases osteocalcin, ALP, BSAP — all osteoblast activity markers) toward bone formation.
4. Anti-inflammatory modulation of bone marrow. The perilesional bone marrow edema in AVN is driven by NF-κB/IL-1β/TNF-α signaling. PEMF's suppression of these pathways (PubMed 19371845) reduces intraosseous pressure, which itself contributes to further ischemia — creating a secondary vicious cycle that PEMF interrupts.

Evidence Base

The strongest PEMF bone evidence comes from fracture and non-union healing, with direct mechanistic overlap to AVN:

• PMID 32495506 (meta-analysis, 14 RCTs, n=1,131): PEMF bone healing rate 79.7% vs 64.3% standard care (RR=1.22, 95%CI 1.10–1.35); healing time reduced (SMD=−1.01); pain reduced (SMD=−0.49).
• PMC6209359 (real-world cohort, n=1,382): 89.6% success rate for PEMF-treated bone healing failures across multiple sites.
• PMC3441225 (tibial non-union, n=44): 77.3% union rate with PEMF in previously failed non-unions — demonstrating efficacy in hypovascular bone environments directly comparable to AVN.
• PMID 35864717 (2022 meta-analysis, PEMF + medications vs medications alone): PEMF significantly increases femoral BMD, lumbar BMD, ALP, BSAP, and osteocalcin (all osteoblast markers) with no increase in adverse events.
• PMC4959873 (mechanism): VEGF upregulation confirmed in PEMF-treated musculoskeletal tissue — the angiogenic foundation of AVN treatment rationale.

Dedicated AVN-PEMF RCTs are limited; the evidence above is drawn from direct mechanistic parallels (avascular bone + osteoblast stimulation + VEGF angiogenesis). Clinicians should position PEMF as an adjunct to the orthopedic management plan, not as a replacement for surgical consultation in Stage II+ patients.

Clinical Protocol

• Coil placement: directly over the affected joint (hip: anterior and/or lateral; knee: medial condyle; shoulder: anterior)
• Session duration: 30–40 minutes
• Frequency: 3–5 sessions per week for the first 8 weeks; 2–3 sessions per week for maintenance
• Course length: minimum 24 sessions (8–12 weeks); follow-up MRI at 12 weeks to assess marrow edema resolution and structural changes
• Monitoring: VAS, patient-reported functional score (WOMAC or HHS for hip), MRI at baseline and 12 weeks

PEMF vs. Conventional AVN Management

Who Is This For?

The optimal PEMF-AVN patient presents with Stage I–II disease, is motivated for non-surgical management, and has a modifiable risk factor (steroid taper already underway, alcohol cessation). Key Philippine patient segments:

• Post-COVID steroid patients: Patients who received high-dose dexamethasone or methylprednisolone in 2020–2022 are now presenting with symptomatic hip and knee AVN. This is a distinct population with typically bilateral involvement and younger average age (30–55 years).
• Trauma patients: Femoral neck fractures (even treated surgically) carry 10–30% risk of post-traumatic femoral head AVN; PEMF as adjunct to surgical fixation may reduce this risk.
• Occupational exposure: Diving workers (dysbaric osteonecrosis) and construction workers (hyperbaric + steroid exposure) represent smaller but addressable clinic segments.

Contraindications

• Active cardiac pacemaker or implanted electronic device
• Pregnancy
• Active malignancy in the treatment field
• Active epilepsy (high-frequency protocols)
• Metallic implants at the treatment site are generally safe with PEMF (not MRI); confirm with referring orthopedic surgeon post-core decompression if drill pins remain in situ

Frequently Asked Questions

Can PEMF reverse avascular necrosis once the bone is already dead?

PEMF cannot restore already-necrotic bone to full health. Its role is to stimulate the viable perilesional tissue — promoting osteoblast activity, angiogenesis into the lesion margin, and slowing progression of the necrotic zone. Early-stage (Ficat I–II) patients with an intact joint surface have the best potential for meaningful structural benefit. Stage III–IV patients benefit primarily from pain reduction and potentially delayed time to total hip replacement.

How soon does pain improve?

Bone marrow edema — which is a major driver of rest pain and night pain in AVN — often responds within 3–6 sessions as the anti-inflammatory phase takes effect. Structural improvement requires 8–16 sessions minimum and is confirmed by repeat MRI at 12 weeks.

Should PEMF replace consultation with an orthopedic surgeon?

No. All AVN patients should be evaluated by an orthopedic surgeon to confirm staging, discuss core decompression candidacy, and establish a monitoring plan. PEMF is most effective as an integrated adjunct within a multidisciplinary orthopedic protocol — not a standalone replacement for medical management.

Clinic Investor Takeaway

Post-COVID AVN has created a distinct new patient cohort in Philippine orthopedic clinics — younger patients (30–55 years), typically bilateral, with ₱500,000–₱1,200,000 hip replacement costs looming on the horizon. A 24-session PEMF course at ₱36,000–₱60,000 represents a compelling non-surgical alternative with referral partnership potential from orthopedic surgeons, rheumatologists, and internal medicine physicians managing post-COVID complications. PEMF clinics positioned as "bone preservation" specialists alongside orthopedic referral networks occupy a defensible, high-value clinical niche with minimal direct competition in the Philippine market.